Shopping Cart 0
Cart Subtotal
USD 0

diabetic nephropathy-pipeline review, h2 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Diabetic Nephropathy-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Nephropathy-Pipeline Review, H2 2017, provides an overview of the Diabetic Nephropathy (Metabolic Disorders) pipeline landscape.

Diabetic nephropathy is the damage to the kidney occurring due to diabetes. It is characterized by albuminuria, reduction in glomerular filtration rate and high blood pressure. Risk factors include obesity, hypertension, high lipid and sugar levels and smoking. This condition is managed by medication and dietary modification.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Nephropathy-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Diabetic Nephropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Nephropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Nephropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 14, 10, 1, 32, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 3 molecules, respectively.

Diabetic Nephropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

-The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy (Metabolic Disorders).

-The pipeline guide reviews pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

-The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

-The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

-The pipeline guide reviews key companies involved in Diabetic Nephropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

-The pipeline guide evaluates Diabetic Nephropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

-The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

-The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders)

Reasons to buy

-Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

-Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

-Find and recognize significant and varied types of therapeutics under development for Diabetic Nephropathy (Metabolic Disorders).

-Classify potential new clients or partners in the target demographic.

-Develop tactical initiatives by understanding the focus areas of leading companies.

-Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

-Formulate corrective measures for pipeline projects by understanding Diabetic Nephropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

-Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Diabetic Nephropathy-Overview 8

Diabetic Nephropathy-Therapeutics Development 9

Pipeline Overview 9

Pipeline by Companies 10

Pipeline by Universities/Institutes 14

Products under Development by Companies 15

Products under Development by Universities/Institutes 19

Diabetic Nephropathy-Therapeutics Assessment 20

Assessment by Target 20

Assessment by Mechanism of Action 23

Assessment by Route of Administration 26

Assessment by Molecule Type 28

Diabetic Nephropathy-Companies Involved in Therapeutics Development 30

AbbVie Inc 30

Allergan Plc 30

Antisense Therapeutics Ltd 31

Aptevo Therapeutics Inc 31

Araim Pharmaceuticals Inc 32

Arena Pharmaceuticals Inc 32

Astellas Pharma Inc 33

AstraZeneca Plc 33

Bayer AG 34

BLR Bio LLC 34

Boehringer Ingelheim GmbH 35

Cellmid Ltd 35

ChemoCentryx Inc 36

CSL Ltd 36

Daiichi Sankyo Company Ltd 37

DiaMedica Therapeutics Inc 37

Dynamis Therapeutics Inc 38

Galectin Therapeutics Inc 38

GenKyoTex SA 39

Gilead Sciences Inc 39

GNI Group Ltd 40

Islet Sciences Inc 40

Johnson & Johnson 41

MediPost Co Ltd 41

Mesoblast Ltd 42

Mitsubishi Tanabe Pharma Corp 42

MorphoSys AG 43

Noxxon Pharma AG 43

Omeros Corp 44

Paranta Biosciences Ltd 44

PhiloGene Inc 45

PhytoHealth Corp 45

ProMetic Life Sciences Inc 46

Redx Pharma Plc 46

Sarfez Pharmaceuticals Inc 47

Serodus ASA 47

Teijin Pharma Ltd 48

Theravance Biopharma Inc 48

Twoxar Inc 49

Vascular Pharmaceuticals Inc 49

Vicore Pharma AB 49

XORTX Pharma Corp 50

Diabetic Nephropathy-Drug Profiles 51

11-RVIVIT-Drug Profile 51

A-717-Drug Profile 52

Antibodies to Inhibit Heparanase for Alopecia, Colitis, Diabetic Nephropathy, Transplantation and Oncology-Drug Profile 53

apararenone-Drug Profile 54

APD-371-Drug Profile 55

APX-115-Drug Profile 57

ASP-8232-Drug Profile 58

atesidorsen sodium-Drug Profile 59

atrasentan hydrochloride-Drug Profile 66

BI-685509-Drug Profile 68

BI-690517-Drug Profile 69

BI-703704-Drug Profile 70

BLR-200-Drug Profile 71

C-21-Drug Profile 72

canagliflozin-Drug Profile 75

CCX-140-Drug Profile 82

Cell Therapy for Chronic Kidney Disease and Metabolic Disorders-Drug Profile 86

cenicriviroc mesylate-Drug Profile 87

cibinetide-Drug Profile 95

CSL-346-Drug Profile 98

Cyndacel-M-Drug Profile 99

DM-199-Drug Profile 101

DM-399-Drug Profile 106

Drugs for Diabetic Nephropathy-Drug Profile 107

DT-23552-Drug Profile 108

DYN-12-Drug Profile 109

emapticap pegol-Drug Profile 111

esaxerenone-Drug Profile 113

finerenone-Drug Profile 116

FM-1302-Drug Profile 118

GKT-136901-Drug Profile 119

GKT-831-Drug Profile 121

GLY-230-Drug Profile 125

GRMD-02-Drug Profile 126

GS-444217-Drug Profile 140

IL-233-Drug Profile 141

IP-9-Drug Profile 142

JD-5037-Drug Profile 143

JNJ-39933673-Drug Profile 144

MG-132-Drug Profile 145

Monoclonal Antibodies to Inhibit MASP-2 for Diabetic Complications and Rheumatoid Arthritis-Drug Profile 146

MOR-107-Drug Profile 148

MPC-300IV-Drug Profile 149

Orbcel-M-Drug Profile 155

PBI-4050-Drug Profile 156

PBI-4425-Drug Profile 164

PBI-4547-Drug Profile 165

PHN-033-Drug Profile 166

pirfenidone-Drug Profile 167

Recombinant Protein for Diabetic Nephropathy-Drug Profile 169

Recombinant Protein to Antagonize VEGFR-2 for Diabetic Nephropathy and Oncology-Drug Profile 170

REDX-06109-Drug Profile 171

SCO-272-Drug Profile 172

SER-150-Drug Profile 173

Small Molecules for Diabetic Nephropathy-Drug Profile 176

Small Molecules to Inhibit AOC3 for Diabetic Nephropathy-Drug Profile 177

Small Molecules to Inhibit Heparanase for Metastatic Cancer and Diabetic Nephropathy-Drug Profile 178

Small Molecules to Inhibit Rho Kinase for Hypertension and Diabetic Nephropathy-Drug Profile 179

SP-20202-Drug Profile 180

Stem Cell Therapy for Diabetic Nephropathy and Autoimmune Disorders-Drug Profile 181

TBE-31-Drug Profile 182

TD-0714-Drug Profile 183

TD-1439-Drug Profile 185

TMX-049-Drug Profile 186

TNFR x TWEAKR-Drug Profile 187

VAR-400-Drug Profile 188

VPI-2690B-Drug Profile 189

VS-105-Drug Profile 190

Wnt-001-Drug Profile 191

XRX-108-Drug Profile 192

XRX-221-Drug Profile 193

Diabetic Nephropathy-Dormant Projects 194

Diabetic Nephropathy-Discontinued Products 197

Diabetic Nephropathy-Product Development Milestones 198

Featured News & Press Releases 198

Appendix 208

Methodology 208

Coverage 208

Secondary Research 208

Primary Research 208

Expert Panel Validation 208

Contact Us 208

Disclaimer 209


List Of Figure

List of Figures

Number of Products under Development for Diabetic Nephropathy, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Diabetic Nephropathy, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Diabetic Nephropathy-Pipeline by AbbVie Inc, H2 2017

Diabetic Nephropathy-Pipeline by Allergan Plc, H2 2017

Diabetic Nephropathy-Pipeline by Antisense Therapeutics Ltd, H2 2017

Diabetic Nephropathy-Pipeline by Aptevo Therapeutics Inc, H2 2017

Diabetic Nephropathy-Pipeline by Araim Pharmaceuticals Inc, H2 2017

Diabetic Nephropathy-Pipeline by Arena Pharmaceuticals Inc, H2 2017

Diabetic Nephropathy-Pipeline by Astellas Pharma Inc, H2 2017

Diabetic Nephropathy-Pipeline by AstraZeneca Plc, H2 2017

Diabetic Nephropathy-Pipeline by Bayer AG, H2 2017

Diabetic Nephropathy-Pipeline by BLR Bio LLC, H2 2017

Diabetic Nephropathy-Pipeline by Boehringer Ingelheim GmbH, H2 2017

Diabetic Nephropathy-Pipeline by Cellmid Ltd, H2 2017

Diabetic Nephropathy-Pipeline by ChemoCentryx Inc, H2 2017

Diabetic Nephropathy-Pipeline by CSL Ltd, H2 2017

Diabetic Nephropathy-Pipeline by Daiichi Sankyo Company Ltd, H2 2017

Diabetic Nephropathy-Pipeline by DiaMedica Therapeutics Inc, H2 2017

Diabetic Nephropathy-Pipeline by Dynamis Therapeutics Inc, H2 2017

Diabetic Nephropathy-Pipeline by Galectin Therapeutics Inc, H2 2017

Diabetic Nephropathy-Pipeline by GenKyoTex SA, H2 2017

Diabetic Nephropathy-Pipeline by Gilead Sciences Inc, H2 2017

Diabetic Nephropathy-Pipeline by GNI Group Ltd, H2 2017

Diabetic Nephropathy-Pipeline by Islet Sciences Inc, H2 2017

Diabetic Nephropathy-Pipeline by Johnson & Johnson, H2 2017

Diabetic Nephropathy-Pipeline by MediPost Co Ltd, H2 2017

Diabetic Nephropathy-Pipeline by Mesoblast Ltd, H2 2017

Diabetic Nephropathy-Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2017

Diabetic Nephropathy-Pipeline by MorphoSys AG, H2 2017

Diabetic Nephropathy-Pipeline by Noxxon Pharma AG, H2 2017

Diabetic Nephropathy-Pipeline by Omeros Corp, H2 2017

Diabetic Nephropathy-Pipeline by Paranta Biosciences Ltd, H2 2017

Diabetic Nephropathy-Pipeline by PhiloGene Inc, H2 2017

Diabetic Nephropathy-Pipeline by PhytoHealth Corp, H2 2017

Diabetic Nephropathy-Pipeline by ProMetic Life Sciences Inc, H2 2017

Diabetic Nephropathy-Pipeline by Redx Pharma Plc, H2 2017

Diabetic Nephropathy-Pipeline by Sarfez Pharmaceuticals Inc, H2 2017

Diabetic Nephropathy-Pipeline by Serodus ASA, H2 2017

Diabetic Nephropathy-Pipeline by Teijin Pharma Ltd, H2 2017

Diabetic Nephropathy-Pipeline by Theravance Biopharma Inc, H2 2017

Diabetic Nephropathy-Pipeline by Twoxar Inc, H2 2017

Diabetic Nephropathy-Pipeline by Vascular Pharmaceuticals Inc, H2 2017

Diabetic Nephropathy-Pipeline by Vicore Pharma AB, H2 2017

Diabetic Nephropathy-Pipeline by XORTX Pharma Corp, H2 2017

Diabetic Nephropathy-Dormant Projects, H2 2017

Diabetic Nephropathy-Dormant Projects, H2 2017 (Contd..1), H2 2017

Diabetic Nephropathy-Dormant Projects, H2 2017 (Contd..2), H2 2017

Diabetic Nephropathy-Discontinued Products, H2 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

AbbVie Inc

Allergan Plc

Antisense Therapeutics Ltd

Aptevo Therapeutics Inc

Araim Pharmaceuticals Inc

Arena Pharmaceuticals Inc

Astellas Pharma Inc

AstraZeneca Plc

Bayer AG

BLR Bio LLC

Boehringer Ingelheim GmbH

Cellmid Ltd

ChemoCentryx Inc

CSL Ltd

Daiichi Sankyo Company Ltd

DiaMedica Therapeutics Inc

Dynamis Therapeutics Inc

Galectin Therapeutics Inc

GenKyoTex SA

Gilead Sciences Inc

GNI Group Ltd

Islet Sciences Inc

Johnson & Johnson

MediPost Co Ltd

Mesoblast Ltd

Mitsubishi Tanabe Pharma Corp

MorphoSys AG

Noxxon Pharma AG

Omeros Corp

Paranta Biosciences Ltd

PhiloGene Inc

PhytoHealth Corp

ProMetic Life Sciences Inc

Redx Pharma Plc

Sarfez Pharmaceuticals Inc

Serodus ASA

Teijin Pharma Ltd

Theravance Biopharma Inc

Twoxar Inc

Vascular Pharmaceuticals Inc

Vicore Pharma AB

XORTX Pharma Corp

Diabetic Nephropathy-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Nephropathy-Pipeline Review, H2 2017, provides an overview of the Diabetic Nephropathy (Metabolic Disorders) pipeline landscape.

Diabetic nephropathy is the damage to the kidney occurring due to diabetes. It is characterized by albuminuria, reduction in glomerular filtration rate and high blood pressure. Risk factors include obesity, hypertension, high lipid and sugar levels and smoking. This condition is managed by medication and dietary modification.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Nephropathy-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Diabetic Nephropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Nephropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Nephropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 14, 10, 1, 32, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 3 molecules, respectively.

Diabetic Nephropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

-The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy (Metabolic Disorders).

-The pipeline guide reviews pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

-The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

-The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

-The pipeline guide reviews key companies involved in Diabetic Nephropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

-The pipeline guide evaluates Diabetic Nephropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

-The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

-The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders)

Reasons to buy

-Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

-Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

-Find and recognize significant and varied types of therapeutics under development for Diabetic Nephropathy (Metabolic Disorders).

-Classify potential new clients or partners in the target demographic.

-Develop tactical initiatives by understanding the focus areas of leading companies.

-Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

-Formulate corrective measures for pipeline projects by understanding Diabetic Nephropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

-Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Diabetic Nephropathy-Overview 8

Diabetic Nephropathy-Therapeutics Development 9

Pipeline Overview 9

Pipeline by Companies 10

Pipeline by Universities/Institutes 14

Products under Development by Companies 15

Products under Development by Universities/Institutes 19

Diabetic Nephropathy-Therapeutics Assessment 20

Assessment by Target 20

Assessment by Mechanism of Action 23

Assessment by Route of Administration 26

Assessment by Molecule Type 28

Diabetic Nephropathy-Companies Involved in Therapeutics Development 30

AbbVie Inc 30

Allergan Plc 30

Antisense Therapeutics Ltd 31

Aptevo Therapeutics Inc 31

Araim Pharmaceuticals Inc 32

Arena Pharmaceuticals Inc 32

Astellas Pharma Inc 33

AstraZeneca Plc 33

Bayer AG 34

BLR Bio LLC 34

Boehringer Ingelheim GmbH 35

Cellmid Ltd 35

ChemoCentryx Inc 36

CSL Ltd 36

Daiichi Sankyo Company Ltd 37

DiaMedica Therapeutics Inc 37

Dynamis Therapeutics Inc 38

Galectin Therapeutics Inc 38

GenKyoTex SA 39

Gilead Sciences Inc 39

GNI Group Ltd 40

Islet Sciences Inc 40

Johnson & Johnson 41

MediPost Co Ltd 41

Mesoblast Ltd 42

Mitsubishi Tanabe Pharma Corp 42

MorphoSys AG 43

Noxxon Pharma AG 43

Omeros Corp 44

Paranta Biosciences Ltd 44

PhiloGene Inc 45

PhytoHealth Corp 45

ProMetic Life Sciences Inc 46

Redx Pharma Plc 46

Sarfez Pharmaceuticals Inc 47

Serodus ASA 47

Teijin Pharma Ltd 48

Theravance Biopharma Inc 48

Twoxar Inc 49

Vascular Pharmaceuticals Inc 49

Vicore Pharma AB 49

XORTX Pharma Corp 50

Diabetic Nephropathy-Drug Profiles 51

11-RVIVIT-Drug Profile 51

A-717-Drug Profile 52

Antibodies to Inhibit Heparanase for Alopecia, Colitis, Diabetic Nephropathy, Transplantation and Oncology-Drug Profile 53

apararenone-Drug Profile 54

APD-371-Drug Profile 55

APX-115-Drug Profile 57

ASP-8232-Drug Profile 58

atesidorsen sodium-Drug Profile 59

atrasentan hydrochloride-Drug Profile 66

BI-685509-Drug Profile 68

BI-690517-Drug Profile 69

BI-703704-Drug Profile 70

BLR-200-Drug Profile 71

C-21-Drug Profile 72

canagliflozin-Drug Profile 75

CCX-140-Drug Profile 82

Cell Therapy for Chronic Kidney Disease and Metabolic Disorders-Drug Profile 86

cenicriviroc mesylate-Drug Profile 87

cibinetide-Drug Profile 95

CSL-346-Drug Profile 98

Cyndacel-M-Drug Profile 99

DM-199-Drug Profile 101

DM-399-Drug Profile 106

Drugs for Diabetic Nephropathy-Drug Profile 107

DT-23552-Drug Profile 108

DYN-12-Drug Profile 109

emapticap pegol-Drug Profile 111

esaxerenone-Drug Profile 113

finerenone-Drug Profile 116

FM-1302-Drug Profile 118

GKT-136901-Drug Profile 119

GKT-831-Drug Profile 121

GLY-230-Drug Profile 125

GRMD-02-Drug Profile 126

GS-444217-Drug Profile 140

IL-233-Drug Profile 141

IP-9-Drug Profile 142

JD-5037-Drug Profile 143

JNJ-39933673-Drug Profile 144

MG-132-Drug Profile 145

Monoclonal Antibodies to Inhibit MASP-2 for Diabetic Complications and Rheumatoid Arthritis-Drug Profile 146

MOR-107-Drug Profile 148

MPC-300IV-Drug Profile 149

Orbcel-M-Drug Profile 155

PBI-4050-Drug Profile 156

PBI-4425-Drug Profile 164

PBI-4547-Drug Profile 165

PHN-033-Drug Profile 166

pirfenidone-Drug Profile 167

Recombinant Protein for Diabetic Nephropathy-Drug Profile 169

Recombinant Protein to Antagonize VEGFR-2 for Diabetic Nephropathy and Oncology-Drug Profile 170

REDX-06109-Drug Profile 171

SCO-272-Drug Profile 172

SER-150-Drug Profile 173

Small Molecules for Diabetic Nephropathy-Drug Profile 176

Small Molecules to Inhibit AOC3 for Diabetic Nephropathy-Drug Profile 177

Small Molecules to Inhibit Heparanase for Metastatic Cancer and Diabetic Nephropathy-Drug Profile 178

Small Molecules to Inhibit Rho Kinase for Hypertension and Diabetic Nephropathy-Drug Profile 179

SP-20202-Drug Profile 180

Stem Cell Therapy for Diabetic Nephropathy and Autoimmune Disorders-Drug Profile 181

TBE-31-Drug Profile 182

TD-0714-Drug Profile 183

TD-1439-Drug Profile 185

TMX-049-Drug Profile 186

TNFR x TWEAKR-Drug Profile 187

VAR-400-Drug Profile 188

VPI-2690B-Drug Profile 189

VS-105-Drug Profile 190

Wnt-001-Drug Profile 191

XRX-108-Drug Profile 192

XRX-221-Drug Profile 193

Diabetic Nephropathy-Dormant Projects 194

Diabetic Nephropathy-Discontinued Products 197

Diabetic Nephropathy-Product Development Milestones 198

Featured News & Press Releases 198

Appendix 208

Methodology 208

Coverage 208

Secondary Research 208

Primary Research 208

Expert Panel Validation 208

Contact Us 208

Disclaimer 209


List Of Figure

List of Figures

Number of Products under Development for Diabetic Nephropathy, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Diabetic Nephropathy, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Diabetic Nephropathy-Pipeline by AbbVie Inc, H2 2017

Diabetic Nephropathy-Pipeline by Allergan Plc, H2 2017

Diabetic Nephropathy-Pipeline by Antisense Therapeutics Ltd, H2 2017

Diabetic Nephropathy-Pipeline by Aptevo Therapeutics Inc, H2 2017

Diabetic Nephropathy-Pipeline by Araim Pharmaceuticals Inc, H2 2017

Diabetic Nephropathy-Pipeline by Arena Pharmaceuticals Inc, H2 2017

Diabetic Nephropathy-Pipeline by Astellas Pharma Inc, H2 2017

Diabetic Nephropathy-Pipeline by AstraZeneca Plc, H2 2017

Diabetic Nephropathy-Pipeline by Bayer AG, H2 2017

Diabetic Nephropathy-Pipeline by BLR Bio LLC, H2 2017

Diabetic Nephropathy-Pipeline by Boehringer Ingelheim GmbH, H2 2017

Diabetic Nephropathy-Pipeline by Cellmid Ltd, H2 2017

Diabetic Nephropathy-Pipeline by ChemoCentryx Inc, H2 2017

Diabetic Nephropathy-Pipeline by CSL Ltd, H2 2017

Diabetic Nephropathy-Pipeline by Daiichi Sankyo Company Ltd, H2 2017

Diabetic Nephropathy-Pipeline by DiaMedica Therapeutics Inc, H2 2017

Diabetic Nephropathy-Pipeline by Dynamis Therapeutics Inc, H2 2017

Diabetic Nephropathy-Pipeline by Galectin Therapeutics Inc, H2 2017

Diabetic Nephropathy-Pipeline by GenKyoTex SA, H2 2017

Diabetic Nephropathy-Pipeline by Gilead Sciences Inc, H2 2017

Diabetic Nephropathy-Pipeline by GNI Group Ltd, H2 2017

Diabetic Nephropathy-Pipeline by Islet Sciences Inc, H2 2017

Diabetic Nephropathy-Pipeline by Johnson & Johnson, H2 2017

Diabetic Nephropathy-Pipeline by MediPost Co Ltd, H2 2017

Diabetic Nephropathy-Pipeline by Mesoblast Ltd, H2 2017

Diabetic Nephropathy-Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2017

Diabetic Nephropathy-Pipeline by MorphoSys AG, H2 2017

Diabetic Nephropathy-Pipeline by Noxxon Pharma AG, H2 2017

Diabetic Nephropathy-Pipeline by Omeros Corp, H2 2017

Diabetic Nephropathy-Pipeline by Paranta Biosciences Ltd, H2 2017

Diabetic Nephropathy-Pipeline by PhiloGene Inc, H2 2017

Diabetic Nephropathy-Pipeline by PhytoHealth Corp, H2 2017

Diabetic Nephropathy-Pipeline by ProMetic Life Sciences Inc, H2 2017

Diabetic Nephropathy-Pipeline by Redx Pharma Plc, H2 2017

Diabetic Nephropathy-Pipeline by Sarfez Pharmaceuticals Inc, H2 2017

Diabetic Nephropathy-Pipeline by Serodus ASA, H2 2017

Diabetic Nephropathy-Pipeline by Teijin Pharma Ltd, H2 2017

Diabetic Nephropathy-Pipeline by Theravance Biopharma Inc, H2 2017

Diabetic Nephropathy-Pipeline by Twoxar Inc, H2 2017

Diabetic Nephropathy-Pipeline by Vascular Pharmaceuticals Inc, H2 2017

Diabetic Nephropathy-Pipeline by Vicore Pharma AB, H2 2017

Diabetic Nephropathy-Pipeline by XORTX Pharma Corp, H2 2017

Diabetic Nephropathy-Dormant Projects, H2 2017

Diabetic Nephropathy-Dormant Projects, H2 2017 (Contd..1), H2 2017

Diabetic Nephropathy-Dormant Projects, H2 2017 (Contd..2), H2 2017

Diabetic Nephropathy-Discontinued Products, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Companies

AbbVie Inc

Allergan Plc

Antisense Therapeutics Ltd

Aptevo Therapeutics Inc

Araim Pharmaceuticals Inc

Arena Pharmaceuticals Inc

Astellas Pharma Inc

AstraZeneca Plc

Bayer AG

BLR Bio LLC

Boehringer Ingelheim GmbH

Cellmid Ltd

ChemoCentryx Inc

CSL Ltd

Daiichi Sankyo Company Ltd

DiaMedica Therapeutics Inc

Dynamis Therapeutics Inc

Galectin Therapeutics Inc

GenKyoTex SA

Gilead Sciences Inc

GNI Group Ltd

Islet Sciences Inc

Johnson & Johnson

MediPost Co Ltd

Mesoblast Ltd

Mitsubishi Tanabe Pharma Corp

MorphoSys AG

Noxxon Pharma AG

Omeros Corp

Paranta Biosciences Ltd

PhiloGene Inc

PhytoHealth Corp

ProMetic Life Sciences Inc

Redx Pharma Plc

Sarfez Pharmaceuticals Inc

Serodus ASA

Teijin Pharma Ltd

Theravance Biopharma Inc

Twoxar Inc

Vascular Pharmaceuticals Inc

Vicore Pharma AB

XORTX Pharma Corp